Assessing the Costs and Cost-Effectiveness of Genomic Sequencing
MetadataShow full item record
CitationChristensen, Kurt D., Dmitry Dukhovny, Uwe Siebert, and Robert C. Green. 2015. “Assessing the Costs and Cost-Effectiveness of Genomic Sequencing.” Journal of Personalized Medicine 5 (4): 470-486. doi:10.3390/jpm5040470. http://dx.doi.org/10.3390/jpm5040470.
AbstractDespite dramatic drops in DNA sequencing costs, concerns are great that the integration of genomic sequencing into clinical settings will drastically increase health care expenditures. This commentary presents an overview of what is known about the costs and cost-effectiveness of genomic sequencing. We discuss the cost of germline genomic sequencing, addressing factors that have facilitated the decrease in sequencing costs to date and anticipating the factors that will drive sequencing costs in the future. We then address the cost-effectiveness of diagnostic and pharmacogenomic applications of genomic sequencing, with an emphasis on the implications for secondary findings disclosure and the integration of genomic sequencing into general patient care. Throughout, we ground the discussion by describing efforts in the MedSeq Project, an ongoing randomized controlled clinical trial, to understand the costs and cost-effectiveness of integrating whole genome sequencing into cardiology and primary care settings.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:24984069